CTOs on the Move

Preferred Commerce

www.preferredcommerce.com

 
Preferred Commerce, Inc. (OCBM) is the supplier and provider of Elev8, products that contain some of the world`s most powerful antioxidants and cell reparation enzymes such as SOD (Superoxide Dismutase) mononucleotides and other key ingredients that promote healthier cell activity in all living things. SOD is an enzyme that alternately catalyzes the dismutation (or partitioning) of the superoxide (O2-) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2). Hydrogen peroxide is also damaging and is degraded by other enzymes such as catalase. Preferred Commerce`s specially formulated Elev8 products have been shown to provide relief to people who have ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Midwest Heart Specialists-Advocate Medical Group

Midwest Heart Specialists-Advocate Medical Group is a Lombard, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Definiti Healthcare Management (DBA)

Definiti Healthcare Management (DBA) is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PathWell

PathWell Health is a Medicare certified home healthcare agency that offers skilled nursing and therapy services to help patients maintain independence and quality of life in the comfort of their own homes.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

Medwise Partners

Medwise Partners is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.